Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice

British Journal of Cancer

Volumn 107, Issue 4, 2012, Pages 658-666

  Edrei, Y ^a   Gross, E ^a   Corchia, N ^a   Abramovitch, R ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

bevacizumab; hemodynamic response imaging; hypercapnia; hyperoxia; liver perfusion

Indexed keywords

ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B20; NITRIC OXIDE; RAPAMYCIN; TL 118; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; HYPERCAPNIA; HYPEROXIA; LIVER METASTASIS; LIVER PERFUSION; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SURVIVAL; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; CIMETIDINE; COLORECTAL NEOPLASMS; CYCLOPHOSPHAMIDE; DICLOFENAC; DISEASE PROGRESSION; DRUG COMBINATIONS; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MICE; NITRIC OXIDE; SULFASALAZINE;

EID: 84864882623     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.322     Document Type: Article

References (49)

1. Abramovitch R, Dafni H, Smouha E, Benjamin LE, Neeman M (1999) In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res 59(19): 5012-5016
2. Abramovitch R, Itzik A, Harel H, Nagler A, Vlodavsky I, Siegal T (2004) Halofuginone inhibits angiogenesis and growth in implanted metastatic rat brain tumor model-an MRI study. Neoplasia 6(5): 480-489
3. Barash H, Gross E, Edrei Y, Pappo O, Spira G, Vlodavsky I, Galun E, Matot I, Abramovitch R (2008) Functional magnetic resonance imaging monitoring of pathological changes in rodent livers during hyperoxia and hypercapnia. Hepatology 48(4): 1232-1241
4. Barash H, Gross E, Matot I, Edrei Y, Tsarfaty G, Spira G, Vlodavsky I, Galun E, Abramovitch R (2007) Functional MR imaging during hypercapnia and hyperoxia: noninvasive tool for monitoring changes in liver perfusion and hemodynamics in a rat model. Radiology 243(3): 727-735
5. Ben-Sasson SA (2008) Anti-cancer therapy comprising an H2-blocker, at least one antiinflammatory agent and a cytotoxic agent. In US Patent 7 838 513
6. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103(2): 159-165
7. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev 8(8): 592-603
8. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60(7): 1878-1886
9. Camp ER, Yang A, Liu W, Fan F, Somcio R, Hicklin DJ, Ellis LM (2006) Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer. Clin Cancer Res 12(8): 2628-2633
10. Chung CH, Lin KT, Chang CH, Peng HC, Huang TF (2009) The integrin alpha2beta1 agonist, aggretin, promotes proliferation and migration of VSMC through NF-kB translocation and PDGF production. Br J Pharmacol 156(5): 846-856
11. Edrei Y, Gross E, Corchia N, Tsarfaty G, Galun E, Pappo O, Abramovitch R (2011) Vascular profile characterization of liver tumors by magnetic resonance imaging using hemodynamic response imaging in mice. Neoplasia 13(3): 244-253
12. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82(1): 4-6
13. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO, Buerk DG, Huang PL, Jain RK (2001) Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 98(5): 2604-2609
14. Gridelli C, Maione P, Rossi A (2008) The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 13(2): 139-147
15. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, Chimenti S, Landsman L, Abramovitch R, Keshet E (2006) VEGFinduced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124(1): 175-189
16. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8(2): 128-135
17. Hellstrand K (2002) Histamine in cancer immunotherapy: a preclinical background. Semin Oncol 29(3 Suppl 7): 35-40
18. Hemingway DM, Angerson WJ, Anderson JH, Goldberg JA, McArdle CS, Cooke TG (1992) Monitoring blood flow to colorectal liver metastases using laser Doppler flowmetry: the effect of angiotensin II. Br J Cancer 66(5): 958-960
19. Howe FA, Robinson SP, McIntyre DJ, Stubbs M, Griffiths JR (2001) Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 14(7-8): 497-506
20. Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, New T, O'Toole K, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Yamashiro DJ, Kandel JJ (2003) Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 100(13): 7785-7790
21. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med 350(23): 2335-2342
22. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706): 58-62
23. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S (2005) Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23(16): 3706-3712
24. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423): 841-844
25. Kubecova M, Kolostova K, Pinterova D, Kacprzak G, Bobek V (2011) Cimetidine: an anticancer drug? Eur J Pharm Sci 42(5): 439-444
26. Li B, Li YY, Tsao SW, Cheung AL (2009) Targeting NF-kappaB signaling pathway suppresses tumor growth, angiogenesis, and metastasis of human esophageal cancer. Molecular Cancer Ther 8(9): 2635-2644
27. Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, Fu L, Malik AK, Gerber HP, Ferrara N, Fuh G (2006) Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281(2): 951-961
28. Losser MR, Lenfant F, Payen D (2010) Modification of the hepatic hemodynamic response to acute changes in PaCO2 by nitric oxide synthase inhibition in rabbits. Anesth Analg 110(3): 845-851
29. Mayorek N, Naftali-Shani N, Grunewald M (2010) Diclofenac inhibits tumor growth in a murine model of pancreatic cancer by modulation of VEGF levels and arginase activity. PloS One 5(9): e12715
30. McLoughlin JM, Jensen EH, Malafa M (2006) Resection of colorectal liver metastases: current perspectives. Cancer Control 13(1): 32-41
31. Meyers MO, Watson JC (2003) Angiogenesis and hepatic colorectal metastases. Surg Oncol Clin N Am 12(1): 151-163
32. Miller KD, Sweeney CJ, Sledge Jr GW (2005) Can tumor angiogenesis be inhibited without resistance? Exs 94: 95-112
33. Moncada S, Palmer RM, Higgs EA (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43(2): 109-142
34. Natori T, Sata M, Nagai R, Makuuchi M (2005) Cimetidine inhibits angiogenesis and suppresses tumor growth. Biomed Pharmacother 59(1-2): 56-60
35. Pasquier E, Kavallaris M, Andre N (2010) Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7(8): 455-465
36. Rowe DH, Huang J, Kayton ML, Thompson R, Troxel A, O'Toole KM, Yamashiro D, Stolar CJ, Kandel JJ (2000a) Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg 35(1): 30-32; discussion 32-33
37. Rowe DH, Huang J, Li J, Manley C, O'Toole KM, Stolar CJ, Yamashiro DJ, Kandel JJ (2000b) Suppression of primary tumor growth in a mouse model of human neuroblastoma. J Pediatr Surg 35(6): 977-981
38. Shankar A, Loizidou M, Burnstock G, Taylor I (1999) Noradrenaline improves the tumour to normal blood flow ratio and drug delivery in a model of liver metastases. Br J Surg 86(4): 453-457
39. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1): 10-29
40. Singh M, Lima A, Molina R, Hamilton P, Clermont AC, Devasthali V, Thompson JD, Cheng JH, Bou Reslan H, Ho CC, Cao TC, Lee CV, Nannini MA, Fuh G, Carano RA, Koeppen H, Yu RX, Forrest WF, Plowman GD, Johnson L (2010) Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 28(6): 585-593
41. Sorbo J, Jakobsson A, Norrby K (1994)Mast-cell histamine is angiogenic through receptors for histamine1 and histamine2. Int J Exper Pathol 75(1): 43-50
42. Tiltan Pharma Ltd (2008) Phase IIB Clinical Trialof Hamsa-1t in Metastatic Castration Resistant Prostate Cancer (CRPC) (TLH-202). http://clinicaltrials.gov/ct2/show/NCT00684970 Tiltan
43. Pharma Ltd (2012) A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment. http://clinicaltrials.gov/ct2/show/NCT01509911
44. Wang Z, Zhou J, Fan J, Tan CJ, Qiu SJ, Yu Y, Huang XW, Tang ZY (2009) Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. J Cancer Res Clin Oncol 135(5): 715-722
45. Warner TD, Mitchell JA (2004) Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. Faseb J 18(7): 790-804
46. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N (1995) Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95(4): 1789-1797
47. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM (2000) Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology 119(5): 1209-1218
48. Weisshardt P, Trarbach T, Durig J, Paul A, Reis H, Tilki D, Miroschnik I, Ergun S, Klein D (2011) Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab. Histochem Cell Biol 137(3): 391-401
49. Yang H, Jager MJ, Grossniklaus HE (2010) Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Invest Ophthalmol Vis Sci 51(6): 2835-2842